Carmine Zoccali Selected Research

Chronic Kidney Failure (Chronic Renal Failure)

02/2008	Urotensin II and Cardiomyopathy in End-Stage Renal Disease.
12/2006	Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?
10/2006	Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease.
07/2006	The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease.
05/2006	Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.
11/2005	Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.
10/2005	The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
09/2005	Low triiodothyronine: a new facet of inflammation in end-stage renal disease.
06/2005	Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.
01/2005	Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients.
08/2004	Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease.
02/2004	Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.
10/2003	Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.
07/2003	Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.
05/2003	Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease.
01/2003	Hepatocyte growth factor and left ventricular geometry in end-stage renal disease.
07/2002	Norepinephrine and concentric hypertrophy in patients with end-stage renal disease.
03/2002	Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.
03/2002	Hypertension in end-stage renal disease: target values, methods of measurement and drug therapy.
02/2002	Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.
01/2002	Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
01/2002	Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Articles by Research Topic

Disease

22	Chronic Kidney Failure (Chronic Renal Failure) 02/2008 - 01/2002
7	Hypertension (High Blood Pressure) 01/2008 - 03/2002
7	Inflammation 03/2007 - 01/2005
3	Cardiomyopathies (Cardiomyopathy) 02/2008 - 06/2005
3	Kidney Diseases (Kidney Disease) 01/2008 - 08/2005
2	Atherosclerosis (Atheroma) 07/2007 - 05/2006
2	Hyperhomocysteinemia 04/2005 - 02/2002
2	Cardiovascular Diseases (Cardiovascular Disease) 08/2004 - 07/2003
1	Left Ventricular Dysfunction 09/2008
1	Anemia 09/2007
1	Infection 03/2007
1	Hypothyroidism 02/2007
1	Carotid Artery Diseases 07/2006
1	Cerebral Infarction 01/2006
1	Thrombosis (Thrombus) 04/2005
1	Arteriovenous Fistula 04/2005
1	Nephrotic Syndrome (Syndrome, Nephrotic) 05/2003
1	Hypertrophy 07/2002
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 07/2002

Drug/Important Bio-Agent (IBA)

5	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2008 - 01/2002
4	Arginine (L-Arginine)FDA Link 03/2007 - 02/2004
3	urotensin IIIBA 02/2008 - 11/2005
3	C-Reactive ProteinIBA 01/2008 - 02/2002
3	CytokinesIBA 12/2006 - 05/2003
3	Triiodothyronine (Liothyronine)FDA Link 10/2006 - 07/2003
3	Biological Markers (Surrogate Marker)IBA 05/2006 - 06/2005
3	Norepinephrine (Noradrenaline)FDA LinkGeneric 02/2004 - 03/2002
3	AdiponectinIBA 05/2003 - 01/2002
2	Neuropeptide YIBA 10/2003 - 07/2003
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2008
1	Simvastatin (Zocor)FDA LinkGeneric 01/2008
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 07/2007
1	E-SelectinIBA 07/2006
1	Uric Acid (Urate)IBA 05/2006
1	ErythropoietinIBA 04/2006
1	Natriuretic PeptidesIBA 11/2005
1	Nitric Oxide Synthase (NO Synthase)IBA 10/2005
1	dimethylarginineIBA 08/2005
1	Insulin (Novolin)FDA Link 01/2005
1	Proteins (Proteins, Gene)IBA 08/2004
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2003

Therapy/Procedure

7	Renal Dialysis (Hemodialysis) 09/2008 - 02/2002
1	Transplants (Transplant) 09/2007
1	Continuous Ambulatory Peritoneal Dialysis (CAPD) 02/2007
1	Drug Therapy (Chemotherapy) 03/2002